Delavirdinum

Delavirdinum Uses, Dosage, Side Effects, Food Interaction and all others data.

A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.

Delavirdinum is a non-nucleoside reverse transcriptase inhibitor (nNRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Delavirdinum binds directly to reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by causing a disruption of the enzyme's catalytic site. The activity of Delavirdinum does not compete with template or nucleoside triphosphates. HIV-2 RT and eukaryotic DNA polymerases (such as human DNA polymerases alpha, beta, or sigma) are not inhibited by Delavirdinum.

Trade Name Delavirdinum
Availability Discontinued
Generic Delavirdine
Delavirdine Other Names Delavirdin, Delavirdina, Delavirdine, Delavirdinum
Related Drugs Biktarvy, Truvada, tenofovir, ritonavir, Complera, Atripla, Stribild
Type
Formula C22H28N6O3S
Weight Average: 456.561
Monoisotopic: 456.194359482
Protein binding

98%

Groups Approved
Therapeutic Class
Manufacturer
Available Country
Last Updated: September 19, 2023 at 7:00 am
Delavirdinum
Delavirdinum

Uses

Delavirdinum is a non-nucleoside reverse transcriptase inhibitor used to treat HIV infection.

For the treatment of HIV-1 infection in combination with appropriate antiretroviral agents when therapy is warranted

Delavirdinum is also used to associated treatment for these conditions: Human Immunodeficiency Virus Type 1 (HIV-1) Infection

How Delavirdinum works

Delavirdinum binds directly to viral reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by disrupting the enzyme's catalytic site.

Toxicity

Major toxicity of delavirdine is rash and should be advised to promptly notify their physician should rash occur. The majority of rashes associated with delavirdine occur within 1 to 3 weeks after initiating treatment with delavirdine. The rash normally resolves in 3 to 14 days and may be treated symptomatically while therapy with delavirdine is continued. Any patient experiencing severe rash or rash accompanied by symptoms such as fever, blistering, oral lesions, conjunctivitis, swelling, muscle or joint aches should discontinue medication and consult a physician.

Food Interaction

  • Take with or without food. The absorption is unaffected by food.

Delavirdinum Disease Interaction

Moderate: achlorhydria, liver disease

Elimination Route

Rapidly absorbed

Half Life

5.8 hours

Elimination Route

Delavirdinum is extensively converted to several inactive metabolites by cytochrome P450 3A (CYP3A). Delavirdinum was excreted in the milk of lactating rats at a concentration three to five times that of rat plasma.

Innovators Monograph

You find simplified version here Delavirdinum

*** Taking medicines without doctor's advice can cause long-term problems.
Share